1. Early Awareness of Alzheimer Disease
2. 3 Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4). https://clinicaltrials.gov/ct2/show/NCT02008357 (accessed May 12, 2022).
3. 4 A donanemab (LY3002813) prevention study in participants with Alzheimer’s disease (TRAILBLAZER-ALZ 3). https://clinicaltrials.gov/ct2/show/NCT05026866 (accessed May 12, 2022).
4. 5 A study to evaluate the efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer’s disease (AD) (SKYLINE). https://clinicaltrials.gov/ct2/show/NCT05256134 (accessed May 12, 2022).
5. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States